Accounts Receivable, after Allowance for Credit Loss, Current of BIO-RAD LABORATORIES, INC. from 31 Dec 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
BIO-RAD LABORATORIES, INC. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Dec 2011 to 31 Dec 2025.
  • BIO-RAD LABORATORIES, INC. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Dec 2025 was $460,600,000, a 1.8% increase year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

BIO-RAD LABORATORIES, INC. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $460,600,000 +$8,100,000 +1.8% 31 Dec 2025 10-K 13 Feb 2026 2025 FY
Q3 2025 $464,700,000 +$2,760,000 +0.6% 30 Sep 2025 10-Q 29 Oct 2025 2025 Q3
Q2 2025 $469,900,000 +$24,394,000 +5.5% 30 Jun 2025 10-Q 31 Jul 2025 2025 Q2
Q1 2025 $424,700,000 -$20,109,000 -4.5% 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $452,500,000 -$36,500,000 -7.5% 31 Dec 2024 10-K 13 Feb 2026 2025 FY
Q3 2024 $461,940,000 +$4,538,000 +0.99% 30 Sep 2024 10-Q 31 Oct 2024 2024 Q3
Q2 2024 $445,506,000 -$46,069,000 -9.4% 30 Jun 2024 10-Q 02 Aug 2024 2024 Q2
Q1 2024 $444,809,000 -$53,464,000 -11% 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 $489,000,000 -$5,645,000 -1.1% 31 Dec 2023 10-K 14 Feb 2025 2024 FY
Q3 2023 $457,402,000 +$25,100,000 +5.8% 30 Sep 2023 10-Q 27 Oct 2023 2023 Q3
Q2 2023 $491,575,000 +$41,251,000 +9.2% 30 Jun 2023 10-Q 04 Aug 2023 2023 Q2
Q1 2023 $498,273,000 +$34,166,000 +7.4% 31 Mar 2023 10-Q 05 May 2023 2023 Q1
Q4 2022 $494,645,000 +$71,108,000 +17% 31 Dec 2022 10-K 16 Feb 2024 2023 FY
Q3 2022 $432,302,000 +$14,588,000 +3.5% 30 Sep 2022 10-Q 28 Oct 2022 2022 Q3
Q2 2022 $450,324,000 +$51,017,000 +13% 30 Jun 2022 10-Q 29 Jul 2022 2022 Q2
Q1 2022 $464,107,000 +$55,970,000 +14% 31 Mar 2022 10-Q 29 Apr 2022 2022 Q1
Q4 2021 $423,537,000 +$4,113,000 +0.98% 31 Dec 2021 10-K 17 Feb 2023 2022 FY
Q3 2021 $417,714,000 +$15,473,000 +3.8% 30 Sep 2021 10-Q 29 Oct 2021 2021 Q3
Q2 2021 $399,307,000 +$38,453,000 +11% 30 Jun 2021 10-Q 30 Jul 2021 2021 Q2
Q1 2021 $408,137,000 +$27,661,000 +7.3% 31 Mar 2021 10-Q 30 Apr 2021 2021 Q1
Q4 2020 $419,424,000 +$26,752,000 +6.8% 31 Dec 2020 10-K 11 Feb 2022 2021 FY
Q3 2020 $402,241,000 +$46,216,000 +13% 30 Sep 2020 10-Q 30 Oct 2020 2020 Q3
Q2 2020 $360,854,000 -$17,050,000 -4.5% 30 Jun 2020 10-Q 31 Jul 2020 2020 Q2
Q1 2020 $380,476,000 -$11,223,000 -2.9% 31 Mar 2020 10-Q 08 May 2020 2020 Q1
Q4 2019 $392,672,000 +$229,000 +0.06% 31 Dec 2019 10-K 16 Feb 2021 2020 FY
Q3 2019 $356,025,000 -$25,501,000 -6.7% 30 Sep 2019 10-Q 01 Nov 2019 2019 Q3
Q2 2019 $377,904,000 -$26,187,000 -6.5% 30 Jun 2019 10-Q 06 Aug 2019 2019 Q2
Q1 2019 $391,699,000 -$38,662,000 -9% 31 Mar 2019 10-Q 10 May 2019 2019 Q1
Q4 2018 $392,443,000 -$72,404,000 -16% 31 Dec 2018 10-K 02 Mar 2020 2019 FY
Q3 2018 $381,526,000 -$38,182,000 -9.1% 30 Sep 2018 10-Q 05 Nov 2018 2018 Q3
Q2 2018 $404,091,000 +$11,249,000 +2.9% 30 Jun 2018 10-Q 09 Aug 2018 2018 Q2
Q1 2018 $430,361,000 +$56,918,000 +15% 31 Mar 2018 10-Q 10 May 2018 2018 Q1
Q4 2017 $464,847,000 +$92,499,000 +25% 31 Dec 2017 10-K 01 Apr 2019 2018 FY
Q3 2017 $419,708,000 +$52,046,000 +14% 30 Sep 2017 10-Q 09 Nov 2017 2017 Q3
Q2 2017 $392,842,000 +$26,561,000 +7.3% 30 Jun 2017 10-Q 07 Aug 2017 2017 Q2
Q1 2017 $373,443,000 -$7,657,000 -2% 31 Mar 2017 10-Q 09 May 2017 2017 Q1
Q4 2016 $372,348,000 -$19,137,000 -4.9% 31 Dec 2016 10-K 16 Apr 2018 2017 FY
Q3 2016 $367,662,000 +$26,114,000 +7.6% 30 Sep 2016 10-Q 02 Nov 2016 2016 Q3
Q2 2016 $366,281,000 +$12,120,000 +3.4% 30 Jun 2016 10-Q 05 Aug 2016 2016 Q2
Q1 2016 $381,100,000 +$38,877,000 +11% 31 Mar 2016 10-Q 06 May 2016 2016 Q1
Q4 2015 $391,485,000 +$13,845,000 +3.7% 31 Dec 2015 10-K 01 Mar 2017 2016 FY
Q3 2015 $341,548,000 -$12,853,000 -3.6% 30 Sep 2015 10-Q 05 Nov 2015 2015 Q3
Q2 2015 $354,161,000 -$24,730,000 -6.5% 30 Jun 2015 10-Q 07 Aug 2015 2015 Q2
Q1 2015 $342,223,000 -$41,705,000 -11% 31 Mar 2015 10-Q 06 May 2015 2015 Q1
Q4 2014 $377,640,000 -$45,020,000 -11% 31 Dec 2014 10-K 29 Feb 2016 2015 FY
Q3 2014 $354,401,000 -$29,070,000 -7.6% 30 Sep 2014 10-Q 07 Nov 2014 2014 Q3
Q2 2014 $378,891,000 -$17,083,000 -4.3% 30 Jun 2014 10-Q 06 Aug 2014 2014 Q2
Q1 2014 $383,928,000 +$6,380,000 +1.7% 31 Mar 2014 10-Q 08 May 2014 2014 Q1
Q4 2013 $422,660,000 +$23,921,000 +6% 31 Dec 2013 10-K 02 Mar 2015 2014 FY
Q3 2013 $383,471,000 +$7,671,000 +2% 30 Sep 2013 10-Q 12 Nov 2013 2013 Q3
Q2 2013 $395,974,000 +$22,157,000 +5.9% 30 Jun 2013 10-Q 08 Aug 2013 2013 Q2
Q1 2013 $377,548,000 -$10,071,000 -2.6% 31 Mar 2013 10-Q 10 May 2013 2013 Q1
Q4 2012 $398,739,000 +$65,000 +0.02% 31 Dec 2012 10-K 18 Mar 2014 2013 FY
Q3 2012 $375,800,000 30 Sep 2012 10-Q 08 Nov 2012 2012 Q3
Q2 2012 $373,817,000 30 Jun 2012 10-Q 09 Aug 2012 2012 Q2
Q1 2012 $387,619,000 31 Mar 2012 10-Q 10 May 2012 2012 Q1
Q4 2011 $398,674,000 31 Dec 2011 10-K 18 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.